| Ytd | -33.67% | |
| 1y | -69.78% |
| Open | 0.98 | Prev Close | 0.99 | Low | 0.95 | High | 0.99 | Mkt Cap | 4.40M |
| Vol | 73.95K | Avg Vol | 158.46K | EPS | -6.01 | P/E | -0.16 | Forward P/E | -0.61 |
| Beta | -1.73 | Short Ratio | 0.39 | Inst. Own | 23.02% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-11 | 50-d Avg | 1.35 | 200-d Avg | 3.53 | 1yr Est | 18.75 |
TPST News
BRISBANE, Calif., July 21, 2026 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST) (“Temp
Advancing a pipeline of in vivo CAR-T product candidates for oncology and immunology applications di
BRISBANE, Calif., July 15, 2026 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST) (“Temp
Gainers Shuttle Pharmaceuticals (NASDAQ:SHPH) shares rose 56.1% to $4.62 during Monday's after-
Gainers OSR Health (NASDAQ:OSRH) stock increased by 7.2% to $0.33 during Wednesday's after-mark
Gainers Quoin Pharmaceuticals (NASDAQ:QNRX) shares rose 40.3% to $4.56 during Tuesday's after-m
BRISANE, Calif., June 04, 2026 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST) (“Tempe
BRISBANE, Calif., May 29, 2026 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST) (the “C
Announced positive interim data from the ongoing REDEEM-1 Phase 1/2a trial of TPST-2003 in patients
BRISBANE, Calif., May 06, 2026 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST) (“Tempe
BRISBANE, Calif., April 29, 2026 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST) (“Tem
Delivery of TPST-2003 lentiviral vector to Cincinnati Children's Applied Gene and Cell Therapy Cente
Adds dedicated business development leadership to support Tempest's strategic priorities Will lead C
ESCA, GRDN, TPST, ASTE and ECG have been added to the Zacks Rank #1 (Strong Buy) List on April 10th,
Completed strategic acquisition of dual-targeting CAR-T assets from Factor Bioscience Inc. Named Mat
Tempest Therapeutics, Inc. (NASDAQ: TPST - Get Free Report) CEO Matthew Angel acquired 231,482 share
Tempest Therapeutics (NASDAQ: TPST - Get Free Report) is projected to announce its Q4 2025 results b
BRISBANE, Calif., March 23, 2026 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST) (the
Shuttle Pharmaceuticals (NASDAQ: SHPH - Get Free Report) and Tempest Therapeutics (NASDAQ: TPST - Ge
Cincinnati Children's Applied Gene and Cell Therapy Center selected to conduct tech transfer, develo
BRISBANE, Calif., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST) (“Temp
Tempest outlines a capital-efficient post-transaction strategy to advance a diversified portfolio of
BRISBANE, Calif., Feb. 04, 2026 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST) (“Temp
Tempest Therapeutics, Inc. (NASDAQ: TPST)'s stock is scheduled to split before the market opens on F
On Tuesday, 386 stocks made new 52-week lows.
On Thursday, 930 stocks hit new 52-week lows.
On Tuesday, 456 stocks hit new 52-week lows.
On Tuesday, 951 companies hit new 52-week lows.
Tuesday's session saw 729 companies set new 52-week lows.
During Tuesday's morning trading, 87 companies set new 52-week lows.